ArticleParkinson's disease2015
Interleukin-6 May Contribute to Mortality in Parkinson's Disease Patients: A 4-Year Prospective Study.
Article in Parkinson's disease, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed.
- A pilot randomized clinical trial examining the effects of Qigong on inflammatory status and sleep quality in people with Parkinson's disease.Journal of bodywork and movement therapies · 2024Trial
- Assessment of the Levels of Level of Biomarkers of Bone Matrix Glycoproteins and Inflammatory Cytokines from Saudi Parkinson Patients.BioMed research international · 2019Trial
- Peripheral immunochemical considerations in Parkinson disease: sources, targets and crosstalk mechanisms.Journal of translational medicine · 2026Review
- Inflammatory cytokine upd3 induces axon length-dependent synapse removal by glia.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Metabolomics in Parkinson's Disease and Correlation with Disease State.Metabolites · 2025Review
- Mitigating Oxidative Stress and Promoting Cellular Longevity with Mushroom Extracts.Foods (Basel, Switzerland) · 2024Article
- LRRK2 G2019S Mutated iPSC-Derived Endothelial Cells Exhibit Increased α-Synuclein, Mitochondrial Impairment, and Altered Inflammatory Responses.International journal of molecular sciences · 2024Article
- How Lifetime Evolution of Parkinson's Disease Could Shape Clinical Trial Design: A Shared Patient-Clinician Viewpoint.Brain sciences · 2024Article
- The Role of IL-6 in Neurodegenerative Disorders.Neurochemical research · 2024Review
- Blocking IL-6 signaling prevents astrocyte-induced neurodegeneration in an iPSC-based model of Parkinson's disease.JCI insight · 2024Article
- The impact of interleukin-6 (IL-6) and mesenchymal stem cell-derived IL-6 on neurological conditions.Frontiers in immunology · 2024Review
- Cytokine activity in Parkinson's disease.Neuronal signaling · 2023Review
- Cytokine profiles of plasma extracellular vesicles as progression biomarkers in Parkinson's disease.Aging · 2023Article
- Blood Biomarkers in Patients with Parkinson's Disease: A Review in Context of Anesthetic Care.Diagnostics (Basel, Switzerland) · 2023Review
- Serum inflammatory cytokines levels and the correlation analyses in Parkinson's disease.Frontiers in cell and developmental biology · 2023Article
- Bilirubin Prevents the THInternational journal of molecular sciences · 2022Article
- Review
- Neuroprotective Effect of Riboflavin Producing Lactic Acid Bacteria in Parkinsonian Models.Neurochemical research · 2022Article
- Biomarker of Neuroinflammation in Parkinson's Disease.International journal of molecular sciences · 2022Review
- WDR43 is a potential diagnostic biomarker and therapeutic target for osteoarthritis complicated with Parkinson's disease.Frontiers in cellular neuroscience · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives. The association between abnormal serum immunomarkers and mortality in 53 consecutive Parkinson's disease patients was studied. Materials and Methods. The plasma level of specific inflammatory cytokines was investigated: mannan-binding lectin (MBL), interleukin- (IL-) 6, and tumor necrosis factor-alpha (TNF-α). The baseline serum immunomarkers obtained from patients who died (n = 16) during a four-year follow-up period were compared with the data of patients who survived (n = 37). Results. The baseline level of IL-6 was significantly higher in the deceased patients than in the survivors. Elevated IL-6 levels and age were major independent contributors to disease mortality. Differences between other plasma cytokine level abnormalities were not significant. Conclusion. This study showed that IL-6 elevation may be a marker of increased mortality risk in Parkinson's disease patients. The inflammation may act in association with other factors and comorbidities in progressive neurodegenerative pathology.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.